by Jordana Choucair | Mar 15, 2022 | Life Sciences
Biogen Inc. will gain full authority over Aduhelm, its controversial Alzheimer’s disease drug, after partner Eisai Co. gave up its rights to make regulatory or sales decisions and share in the profits for the treatment. The drug’s outlook has weakened...
by Jordana Choucair | Mar 14, 2022 | Life Sciences
Pfizer CEO Albert Bourla said on Sunday that a fourth dose of the COVID-19 vaccine will be necessary to continue to help keep hospitalizations manageable and sicknesses milder. He said Pfizer plans to submit data for a fourth COVID-19 dose, and then see what...
by Jordana Choucair | Mar 14, 2022 | Life Sciences
Sanofi SA’s experimental breast cancer treatment failed in a clinical trial, marking a setback for the drugmaker, which had prioritized the medicine and called it “potentially transformative.” In the phase two study, patients with advanced disease...
by Jordana Choucair | Mar 9, 2022 | Life Sciences
Pfizer Inc. said it began testing its antiviral pill to treat COVID-19 among children at high risk of severe illness. The study seeks to measure whether the pill can keep newly infected kids out of the hospital. Trial results are expected by the end of the year, and...
by Jordana Choucair | Mar 9, 2022 | Life Sciences
Congress moved to grant the FDA new authority over synthetic nicotine, which some e-cigarette makers have adopted in recent years to avoid the agency’s crackdown on vapes that use nicotine extracted from tobacco. Under the legislation, which is included in the...
by Jordana Choucair | Mar 8, 2022 | Life Sciences
House Energy and Commerce Chair Frank Pallone introduced a bill that would dramatically rein in the FDA’s accelerated approval program. Under accelerated approval pathway, the FDA can approve drugs without clear evidence that they actually prolong patients’ lives, so...
Recent Comments